6.
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S
. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615.
PMC: 7745181.
DOI: 10.1056/NEJMoa2034577.
View
7.
McMenamin M, Nealon J, Lin Y, Wong J, Cheung J, Lau E
. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022; 22(10):1435-1443.
PMC: 9286709.
DOI: 10.1016/S1473-3099(22)00345-0.
View
8.
Townsend J, Hassler H, Wang Z, Miura S, Singh J, Kumar S
. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe. 2021; 2(12):e666-e675.
PMC: 8486316.
DOI: 10.1016/S2666-5247(21)00219-6.
View
9.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P
. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111.
PMC: 7723445.
DOI: 10.1016/S0140-6736(20)32661-1.
View
10.
Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O
. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416.
PMC: 8489881.
DOI: 10.1016/S0140-6736(21)02183-8.
View
11.
Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G
. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651.
PMC: 8848203.
DOI: 10.1001/jama.2022.0470.
View
12.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J
. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720.
PMC: 7092819.
DOI: 10.1056/NEJMoa2002032.
View
13.
Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Ipekci A
. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020; 17(9):e1003346.
PMC: 7508369.
DOI: 10.1371/journal.pmed.1003346.
View
14.
Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C
. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686.
PMC: 8942855.
DOI: 10.1038/s41586-022-04411-y.
View
15.
Yan H, Zhu Y, Gu J, Huang Y, Sun H, Zhang X
. Better strategies for containing COVID-19 pandemic: a study of 25 countries via a vSIADR model. Proc Math Phys Eng Sci. 2022; 477(2248):20200440.
PMC: 8300607.
DOI: 10.1098/rspa.2020.0440.
View
16.
Michlmayr D, Holm Hansen C, Gubbels S, Valentiner-Branth P, Bager P, Obel N
. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg Health Eur. 2022; 20:100452.
PMC: 9245510.
DOI: 10.1016/j.lanepe.2022.100452.
View
17.
Dashtbali M, Mirzaie M
. A compartmental model that predicts the effect of social distancing and vaccination on controlling COVID-19. Sci Rep. 2021; 11(1):8191.
PMC: 8046797.
DOI: 10.1038/s41598-021-86873-0.
View
18.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E
. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546.
PMC: 8908811.
DOI: 10.1056/NEJMoa2119451.
View
19.
Yoon S, Hegmann K, Thiese M, Burgess J, Ellingson K, Lutrick K
. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022; 386(19):1855-1857.
PMC: 9006784.
DOI: 10.1056/NEJMc2201821.
View
20.
Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W
. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021; 4(12):e2137257.
PMC: 8672238.
DOI: 10.1001/jamanetworkopen.2021.37257.
View